Louis Moore Bacon's PRME Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 500,000 shares of Prime Medicine, Inc. (PRME) worth $2.77 M, representing 0.04% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in PRME, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 500,000 shares. Largest reduction occurred in Q4 2023, reducing 446,733 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Prime Medicine (PRME) Holding Value Over Time
Track share changes against reported price movement
Quarterly Prime Medicine (PRME) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2022 | +500,000 | New Buy | 500,000 | $18.58 |
| Q2 2023 | -53,267 | Reduce 10.65% | 446,733 | $14.65 |
| Q4 2023 | -446,733 | Sold Out | 0 | $0.00 |
| Q1 2024 | +500,000 | New Buy | 500,000 | $7.00 |
Louis Moore Bacon's Prime Medicine Investment FAQs
Louis Moore Bacon first purchased Prime Medicine, Inc. (PRME) in Q4 2022, acquiring 500,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Prime Medicine, Inc. (PRME) for 12 quarters since Q4 2022.
Louis Moore Bacon's largest addition to Prime Medicine, Inc. (PRME) was in Q4 2022, adding 500,000 shares worth $9.29 M.
According to the latest 13F filing for Q3 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 500,000 shares of Prime Medicine, Inc. (PRME), valued at approximately $2.77 M.
As of the Q3 2025 filing, Prime Medicine, Inc. (PRME) represents approximately 0.04% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Prime Medicine, Inc. (PRME) was 500,000 shares, as reported at the end of Q4 2022.